Related Experiment Video
Updated: Aug 31, 2025

Inducible and Reversible Dominant-negative DN Protein Inhibition
Published on: January 7, 2019
BAP1 maintains HIF-dependent interferon beta induction to suppress tumor growth in clear cell renal cell carcinoma
Lauren E Langbein1, Rayan El Hajjar1, Shen He1
1Department of Pathology, Anatomy, & Cell Biology, Thomas Jefferson University, Philadelphia, PA, United States.
Abstract:
BRCA1-associated protein 1 (BAP1) is a deubiquitinase that is mutated in 10-15% of clear cell renal cell carcinomas (ccRCC). Despite the association between BAP1 loss and poor clinical outcome, the critical tumor suppressor function(s) of BAP1 in ccRCC remains unclear. Previously, we found that hypoxia-inducible factor 2α (HIF2α) and BAP1 activate interferon-stimulated gene factor 3 (ISGF3), a transcription factor activated by type I interferons and a tumor suppressor in ccRCC xenograft models. Here, we aimed to determine the mechanism(s) through which HIF and BAP1 regulate ISGF3. We found that in ccRCC cells, loss of the von Hippel-Lindau tumor suppressor (VHL) activated interferon beta (IFN-β) expression in a HIF2α-dependent manner. IFN-β was required for ISGF3 activation and suppressed the growth of Ren-02 tumors in xenografts. BAP1 enhanced the expression of IFN-β and stimulator of interferon genes (STING), both of which activate ISGF3. Both ISGF3 overexpression and STING agonist treatment increased ISGF3 activity and suppressed BAP1-deficient tumor growth in Ren-02 xenografts. Our results indicate that BAP1 loss reduces type I interferon signaling, and reactivating this pathway may be a novel therapeutic strategy for treating ccRCC.
Insights
Loss of BRCA1-associated protein 1 (BAP1) in clear cell renal cell carcinoma (ccRCC) impairs type I interferon signaling. Reactivating this pathway offers a potential therapeutic strategy for ccRCC.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- BRCA1-associated protein 1 (BAP1) is frequently mutated in clear cell renal cell carcinoma (ccRCC), correlating with poor outcomes.
- The tumor suppressor functions of BAP1 in ccRCC pathogenesis are not fully understood.
- Hypoxia-inducible factor 2α (HIF2α) and BAP1 were previously shown to activate interferon-stimulated gene factor 3 (ISGF3), a tumor suppressor in ccRCC models.
Purpose of the Study:
- To elucidate the mechanisms by which hypoxia-inducible factors (HIF) and BAP1 regulate ISGF3 activity in ccRCC.
- To investigate the role of type I interferon signaling in BAP1-deficient ccRCC.
Main Methods:
- Utilized ccRCC cell lines and xenograft models.
- Investigated gene expression of interferon beta (IFN-β) and stimulator of interferon genes (STING).
- Assessed ISGF3 activation through overexpression and STING agonist treatment.
Main Results:
- Loss of the von Hippel-Lindau tumor suppressor (VHL) in ccRCC cells induced IFN-β expression in a HIF2α-dependent manner.
- IFN-β was essential for ISGF3 activation and inhibited tumor growth in xenografts.
- BAP1 positively regulated IFN-β and STING expression, thereby enhancing ISGF3 activity.
- Restoring ISGF3 activity via overexpression or STING agonism suppressed BAP1-deficient tumor growth.
Conclusions:
- BAP1 loss diminishes type I interferon signaling in ccRCC.
- Reactivation of the type I interferon pathway presents a promising therapeutic avenue for ccRCC treatment.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Inhibition of Cdk Activity
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

